Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, umbrella study aimed to evaluate the combined,
biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and
Nab-paclitaxel in patients with platinum-resistant recurrent ovarian cancer (PROC).
Phase:
Phase 2
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Affiliated Hospital of Jiangnan University Anhui Provincial Cancer Hospital Beijing Cancer Hospital First Affiliated Hospital, Sun Yat-Sen University Hubei Cancer Hospital Hunan Cancer Hospital Jilin Provincial Tumor Hospital Obstetrics and Gynecology Hospital of Zhejiang University Qilu Hospital of Shandong University Sun Yat-sen University